Pangu BioPharma is a subsidiary of aTyr Pharma based in Hong Kong. The work at Pangu BioPharma is focused on identifying and characterizing the broad class of Physiocrine™ family, which is an entirely new product class with extensive applications in treating human disease. Although tRNA synthetases are universal and essential components of the protein synthesis machinery in all organisms, human synthetases have naturally occurring resected variants - Physiocrines ™ - with potent cell signaling activities distinct from the protein synthesis activities. These novel signaling proteins are vital to normal functioning of humans.
Pangu BioPharma is the result of an innovative partnership between aTyr Pharma and the Hong Kong University of Science and Technology (HKUST) with project funding from the Innovation and Technology Commission (ITC) of Hong Kong. Pangu is using next generation sequencing approaches in splice variant identification and leveraging the neurobiology expertise at HKUST.